We are live on ! Find out more
BNTX icon

BioNTech

320 hedge funds and large institutions have $6.02B invested in BioNTech in 2022 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 103 increasing their positions, 84 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 17

23% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 84

21% more funds holding

Funds holding: 264320 (+56)

20% more capital invested

Capital invested by funds: $5B → $6.02B (+$1.01B)

1.07% more ownership

Funds ownership: 15.29%16.35% (+1.1%)

17% less call options, than puts

Call options by funds: $349M | Put options by funds: $421M

22% less funds holding in top 10

Funds holding in top 10: 97 (-2)

Holders
320
Holders Change
+56
Holders Change %
+21.21%
% of All Funds
5.14%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.11%
New
76
Increased
103
Reduced
84
Closed
17
Calls
$349M
Puts
$421M
Net Calls
-$71.2M
Net Calls Change
+$60.9M
Name Holding Trade Value Shares
Change
Change in
Stake
SGA
101
Sector Gamma AS
Norway
$3.57M +$3.65M +23,738 New
DA
102
Duality Advisers
Florida
$3.52M +$2.04M +13,267 +130%
ECM
103
Endurant Capital Management
California
$3.25M +$3.33M +21,664 New
Cerity Partners
104
Cerity Partners
New York
$3.09M +$3.17M +20,576 New
SG Americas Securities
105
SG Americas Securities
New York
$3.01M -$7.04M -45,734 -70%
TAAM
106
Top Ace Asset Management
Hong Kong
$3M +$3.08M +20,000 New
Envestnet Asset Management
107
Envestnet Asset Management
Illinois
$2.94M +$23.5K +153 +0.8%
BAM
108
Belpointe Asset Management
Nevada
$2.9M +$1.47M +9,545 +98%
CUAMC
109
China Universal Asset Management Company
China
$2.86M +$2.81M +18,240 +2,211%
BFM
110
Boothbay Fund Management
New York
$2.71M +$2.77M +18,032 New
CI
111
Capital International
California
$2.65M +$245K +1,593 +10%
CSS
112
Cubist Systematic Strategies
Connecticut
$2.56M +$1.75M +11,361 +201%
Amundi
113
Amundi
France
$2.53M +$126K +821 +5%
OC
114
Oppenheimer & Co
New York
$2.47M +$597K +3,877 +31%
Squarepoint
115
Squarepoint
New York
$2.36M +$2.42M +15,696 New
GC
116
Guggenheim Capital
Illinois
$2.3M -$358K -2,328 -13%
RJFSA
117
Raymond James Financial Services Advisors
Florida
$2.24M +$255K +1,660 +13%
RJA
118
Raymond James & Associates
Florida
$2.14M -$938K -6,095 -30%
Capital Fund Management (CFM)
119
Capital Fund Management (CFM)
France
$2.07M -$3.02M -19,644 -59%
Zurich Cantonal Bank
120
Zurich Cantonal Bank
Switzerland
$2.04M -$302K -1,965 -13%
CIS
121
Capital International Sarl
California
$2.01M +$379K +2,460 +23%
DnB Asset Management
122
DnB Asset Management
Norway
$1.97M +$2.02M +13,118 New
Russell Investments Group
123
Russell Investments Group
United Kingdom
$1.96M -$332K -2,158 -14%
SGH
124
Sivik Global Healthcare
Connecticut
$1.95M +$2M +13,000 New
BPC
125
Banque Pictet & Cie
Switzerland
$1.95M -$5.69M -36,982 -74%

BNTX Hedge Fund Activity: Q4 2022 in Review

320 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2022, worth a combined $6.02B — up 20% from $5B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new BNTX positions and 17 closed out — a net gain of 59 holders — while 103 added to existing stakes and 84 trimmed.

The largest buyer was BlackRock, adding an estimated $84M. The largest seller was Fosun International, exiting entirely with an estimated $103M sold.

  • 320 institutional investors held BioNTech (BNTX) as of Q4 2022, up from 264 in Q3 2022.
  • Funds reported $6.02B of BioNTech stock for Q4 2022, up 20% quarter-over-quarter.
  • 76 funds opened new BioNTech positions in Q4 2022 and 17 closed out, a net change of +59 holders.
  • The largest BioNTech buyer in Q4 2022 was BlackRock, an estimated $84M added.
  • The largest BioNTech seller in Q4 2022 was Fosun International, an estimated $103M sold.

Based on aggregated 13F filings for Q4 2022.